HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Why Plan B Matters

This article was originally published in RPM Report

Executive Summary

While Barr's attempt to switch the emergency contraceptive Plan B to over-the-counter status is immaterial to the company, the rest of the drug industry can't afford to ignore the controversy, which could jeopardize the renewal of crucial legislation that supports fast and predictable reviews of all new drugs. Moreover, FDA may be reopening old controversies, like whether third parties can force an OTC switch against a brand company's wishes.

You may also be interested in...



Why Wait? Investors Can Expect a More Proactive, Aggressive FDA

Comments made by former FDA offi cials and incoming leadership describe a scenario of nearcrisis and rock-bottom morale. Agency management is taking aggressive action to address those concerns. Investors have zeroed in on the new Commissioner(s).

As DC Speculates on Democrats in 2009, Some Old FDA Hands Come Into View

No matter who wins, the 2008 Presidential election means there will be widespread personnel changes across key federal health agencies. Two ex-FDA officials look particularly ready to resurface should the Democrats take back the White House.

Plan B Approval Is Good News for OTC Switch of Xenical

FDA's fitful handling of Barr's OTC switch application for the emergency contraceptive Plan B has provided great political theater. But for GSK and Roche, the issue was a complication for the OTC switch of the weight loss drug orlistat. Now the path looks clear.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS126062

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel